Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page’s footer revision label has been updated from v3.5.2 to v3.5.3, reflecting a site software/version change rather than a change to the clinical trial record.SummaryDifference0.0%

- Check23 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check45 days agoChange DetectedAdrenal cortex carcinoma was added as a lay term for Adrenocortical Carcinoma in the Conditions section.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; the page now shows Revision: v3.4.3.SummaryDifference0.0%

- Check87 days agoChange DetectedThe footer now displays Revision: v3.4.2, replacing Revision: v3.4.1.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.